Recently MetaReports.net published an exhaustive research report on Neocardiogenesis, the phenomenon that is revolutionizing regenerative medicine and creating new and novel options for treatment of ischemic heart disease. Scope of that report precluded us from delving too much into areas peripheral to the primary focus of the report. Nevertheless some of those issues are very pertinent to understanding the rapidly evolving history and landscape of regenerative cardiology. So we decided to address those issues in brief satellite reports that supplement our research on Neocardiogenesis.

In this report we take a close look at the two pioneers that are still active in their quest to get the brand new regenerative cardiology industry rolling. Two companies defied the giants of the industry in keeping their pursuit alive. When the likes of Genentech, Chiron (Novartis) and Scios (Johnson & Johnson) stepped out they stayed their course. A few others entered the fray and left, but two companies kept company in their pursuit. The promoters of Cardium Therapeutics, Inc. and CardioVascular BioTherapeutics, Inc. spent well over a decade hunting for a viable product to grow coronary arteries in patients with ischemic heart disease. The TWO have been striving to develop biological products that they believe will facilitate natural bypass to blocked coronary arteries. Will their efforts bear fruits?

This tale of the TWO is climaxed by a rush of new enthusiasts who are fast changing the regenerative cardiology landscape. Fueled by California's $3 billion dollar Proposition 71, stem cell initiative and complemented by other well-funded stem cell research programs worldwide, regenerative cardiology is nothing less than the Gold Rush of the 21st century. New entrants are busying the scene. From a few players in the late 90s - almost all of them except the TWO succumbing to the rigors of translational research - today there are more than 80 companies in the renewed rush to conquer drug development industry's toughest terrain. The TWO have seen it all. The paradigm shift that challenged the age old belief that heart tissue cannot regenerate. The consensus amongst opinion leaders that adult heart is no more a postmitotic organ, and cardiomyocytes can indeed be regenerated. The TWO stayed unperturbed by the brunt of the epoch making new knowledge. From growing the coronary collaterals to the concept of regenerating myocardium. From triggering of coronary angiogenesis to induction of cardiac myogenesis. The TWO have navigated their course through all of those changing scenarios.

There are dozens of market research reports published on Cardium and CVBT, pricing their intellectual properties, estimating their future earning potential, forecasting the value of their stock, recommending, buy, hold or sell on their securities. All of these reports are financial projections by investment consultants built entirely upon the presumptions of a sustainable technology platform. If the technology platform is robust the projections presumably may stand. If it is vulnerable the projections crumble like a house of cards. This report is an exhaustive review of their technology, their products, their strategy, and all the clinical and pre-clinical data on which their business development strategy is based. All of it constitutes valuable intelligence for anyone with interest and stakes in the business of regenerative medicine.

Irrespective of the fact that the TWO rise or fall, they have made themselves a place in this niche industry that has arrived to stay - the business of rebuilding the broken hearts. This is a tale of the TWO for their peers to inspire, for their critics to mellow down, for their supporters to see the big picture, for their investors to get real, and for the TWO to learn from the lessons of the long roller coaster ride that brought them to where they are today.